Since the early groundbreaking experiments, this exploding field has been propelled by our appreciation for the complexity of cancer, our thirst to understand the Genetically engineered mouse models have contributed extensively to the field of cancer research. The molecular and cellular basis for its development, our desperate need for better preclinical models to test ability to manipulate the mouse germline affords numerous approaches toward understanding the comnovel treatment and prevention strategies, and the development of increasingly refined technologies for maplexities of this disease, possibly providing accurate preclinical models for therapeutic and diagnostic adnipulating gene expression and mutation in the mouse. This review highlights some of the current strategies for vances. This review highlights some of the current strategies for modeling cancer in the mouse, recent modeling cancer in the mouse, some recent accomplishments in the field, and important remaining challenges. accomplishments, and key remaining challenges.
Figure 1. Strategies for Modeling Cancer in the Mouse
Many of the current approaches for creating mice with specific genetic lesions and the resulting potential for cell specificity of alterations are diagrammed. The methods involve either the production of transgenic mice with random gene insertions, usually by pronuclear DNA injection (in the diagram, mice with tails), or of mice with targeted mutations of endogenous genes via embryonic stem (ES) cell manipulation (designated by mice without tails). Basic strategies are shown in (A) and (B), respectively. A gene of interest (GOI), for example an oncogene, can be expressed cell specifically in transgenic mice using a cell specific promoter (CSP) (A). While the gene is present in every cell and thus transmitted through the germline, expression is most often dictated by the associated regulatory elements, but can be influenced by the site(s) of random insertion. Generally, expression is not achieved in every cell, but is usually widespread (as indicated by the light blue nuclei). Careful assessment of each founder line is required to ascertain the extent and specificity of expression. Standard targeting strategies in ES cells can be used to alter endogenous genes to create null (knock-out, as diagrammed in [B] ) or other specific mutations (knock-in). In this case, a mouse strain is generated that carries the engineered alteration in every cell (designated by an asterisk); cell specificity of expression is dictated by the endogenous regulatory signals. Strategies in (C)-(G) offer conditional control of either transgene expression (C-E) or endogenous gene mutation (F and G). In (C), the GOI is regulated by transcriptional response elements (RE) of a transcriptional activator (TA) that is expressed in transgenic mice via a CSP. In the most versatile cases (e.g., tetracycline-regulated activator, lac-I repressor, ecdysone receptor), TA function can be regulated by introduction of a small molecule. In this case, expression of the transgene is reversible, and the effects of expression or expression cessation can be assessed at specific times. Cell specificity is dictated by a CSP driving the TA. Since regulation is at the level of transcription, stability of the transgenic protein must be considered when assessing the effect of shut off. Activity of the transgenic protein can be regulated when using the strategy depicted in (D). In this case, the GOI is fused to a segment encoding a ligand-regulated protein domain. For example, the estrogen receptor ligand-binding domain has been used effectively to regulate transgenic proteins.
Strategies in (E)-(G) utilize a recombinase (xase) and its cognate binding site (yellow triangles) to induce deletions resulting in expression of a transgene (E), an endogenous gene (G), or in a specific mutation (F). The recombinase can be introduced by crosses with transgenic mice expressing the xase cell specifically (as in [A]-[C]
) or by limited introduction via injection into a specific organ. In the latter case, viral vectors have been used to successfully introduce the xase. However, it may be possible to introduce the protein directly if it is modified appropriately. By introducing the xase somatically, it is possible to achieve the desired alteration in a limited number of cells so as to model the stochastic nature of events that produce cancer in humans. Finally, many of these strategies can be used in combination to achieve even greater control of where and when desired changes occur. In diagrams of a simple tissue with two cell types present, cells expressing a transgene or harboring an expressed lesion harbor light blue nuclei. In (B), an asterisk indicates cells carrying a specific targeted mutation. Increased cell numbers indicate a potential cellular oncogenic response.
In addition to establishing cause and effect relational., 1994, and references therein). These responses predispose to the focal emergence of tumors, a sign that ships, broad alteration of cancer genes in the mouse has also provided the foundation for studying tumor additional events have occurred in 
, 2001). A variation of this approach was
In part to address the degree to which current mouse recently used to generate mouse tumors resembling cancer models satisfy these criteria, as well as to spur human ovarian carcinomas. Since no ovary-specific prothe development of more sophisticated models, the Namoter has been identified, ovarian cells expressing TVA tional Cancer Institute (NCI) established the mouse modunder a more general promoter were infected in vitro els of human cancer consortium ( which lack the ability to upregulate telomerase. In the That is, even if tumor progression does not "look" presence of a p53 mutation, the combination of short exactly the same in the two species, the genes and telomeres and no telomerase led to increased tumor pathways affected may be the same or related. In the incidence and a broader range of tumor types including emerging era of targeted approaches to therapy and carcinomas, which only rarely arise in p53 Ϫ/Ϫ mice with prevention, the commonality of the molecular events is normal telomere lengths (Artandi et al., 2000). Imporof even greater importance. As discussed above, the tantly, tumors from these animals had a dramatically most obvious consideration in this regard is the design elevated frequency of nonreciprocal translocations, of the initiating mutations (whether they be expression which are common in human cancer but rare in mice. of specific oncogenes or inactivation of specific TSG or
Fine mapping of such translocations may lead to the DNA repair genes) to most closely mimic those known discovery of new cancer-associated genes. In a followto occur in given human tumor types. to the Apc Min mutation, however, the Blm M3 mutation As reviewed above, some GEM models have been highly dramatically increased the number of intestinal polyps useful for studying the biology of tumor progression.
and, importantly, many tumors had lost the wild-type However, a common feature of many mouse tumor modApc allele though mitotic recombination as opposed to els is that they represent mainly the early stages of the usual mechanism of chromosome loss. Thus, the disease development and relatively few recapitulate the Blm M3 mutation may represent a useful tool for increasfeatures of advanced human cancer, including high freing somatic mutation rates in cancer modeling and at the quency metastasis. One possible explanation for this same time allow for more precise mapping of recessive important difference is that the lifespan of the laboratory mutations that contribute to tumor development. Addimouse is two to three years, while tumorigenesis in tional methods for increasing mutation rates in tumor modeling include the use of retroviruses as insertional humans can take several decades to progress to the tested the response of different transgenic models of As discussed above, the requirement of continuous breast cancer to doxorubicin and paclitaxel. Consideroncogenic stimulation for tumor maintenance has reably more work of this sort is needed to establish cently been examined, and these studies provide proof whether GEM models will be better suited to predict the of principle for therapies targeted against particular course of cancer therapy in the future. gene products or pathways. GEM models have also been used to examine the efficacy of some targeted
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